Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
- Development stage
- Unknown
- Lead developer
- Astex Pharmaceuticals
- Modality
- Small Molecules
01
Overview
4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE is a synthetic small molecule belonging to the class of benzamides. It is formed by the formal condensation of 4-phenoxybenzoic acid's carboxy group with the amino group of (pyridin-2-yl)methylamine. This compound functions as an inhibitor of protein-serine/threonine kinases, specifically interfering with the action of mitogen-activated protein kinase (MAPK).
- Other names
- 4-PHENOXY-N-(2-PYRIDINYLMETHYL)BENZAMIDEBENZAMIDE, 4-PHENOXY-N-(2-PYRIDINYLMETHYL)-CHEBI:41135
02
Targets
MAPK14 (p38 mitogen-activated protein kinase alpha)
Beyond the preview
Go deeper on 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE.